Valpropylhydroxamic Acid

Valpropylhydroxamic Acid

SCHEMBL15310210

CCCC(CCC)C(=O)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 10/20 1.00
HDAC6 Q9UBN7 7/20 1.00
HDAC7 Q8WUI4 4/20 1.00
HDAC9 Q9UKV0 4/20 1.00
HDAC5 Q9UQL6 4/20 1.00
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
HDAC1 Q13547 8/20 0.52
HDAC2 Q92769 7/20 0.52
CHRM1 P11229 1/20 0.52
AKR1A1 P14550 1/20 0.52
CHRM3 P20309 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
ADRA1A P35348 1/20 0.52
HRH1 P35367 1/20 0.52
DRD3 P35462 1/20 0.52
SLC6A3 Q01959 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HDAC3 O15379 7/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18520585 0.91 HDAC8 (0.83) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL28473668 0.85 CA2 (0.83) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL19910585 0.81 CA2 (0.70) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL24932772 0.81 CA2 (0.70) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL7750482 0.81 CA2 (0.70) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL3367550 0.79 HDAC7 (0.65) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL12864235 0.78
SCHEMBL3049838 0.77
SCHEMBL28686448 0.77 HDAC8 (0.62) HDAC8HDAC6HDAC7HDAC9HDAC5
SCHEMBL28987848 0.77 CA1 (0.63) HDAC8HDAC6HDAC7HDAC9HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024072204-A1 PROCESS FOR PRODUCING NANOMETRE-SIZED METALLIC SOAPS SILVER TECH DE MEXICO SA DE CV (MX) 2024-04-04 WO claimed
EP-4694679-A2 DEGRADABLE FISHING LINES AND NETS Enviro Cast, LLC (US) 2026-02-18 EP disclosed
WO-2025075493-A1 COMPOSITION FOR SWEETENING BEVERAGES, FOOD AND DESSERTS, IN THE FORM OF A POWDER FOR MAKING FLAVOURED SYRUPS BARRAGAN ESPINOSA GEORGINA (MX) 2025-04-10 WO disclosed
EP-4532552-A1 METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES Provention Bio, Inc. (US) 2025-04-09 EP disclosed
WO-2025072291-A1 ZEIN COATED OR IMPREGNATED PAPER STRAWS AND RELATED TUBULAR ARTICLES KALYKOS LLC (US) 2025-04-03 WO disclosed
WO-2025037130-A1 TIO2-BASED MATERIAL (TIO2-NP), AND METHOD FOR THE SYNTHESIS THEREOF, HAVING A MULTIFUNCTIONAL AND VERSATILE PROPERTY FOR THE SIMULTANEOUS AND ONE-STEP PHOTO-OXIDATION AND ADSORPTION OF DIFFERENT POLLUTANTS, SUCH AS ARSENIC, ALUMINIUM, BARIUM, BORON, IRON, LITHIUM, MANGANESE, MOLYBDENUM, STRONTIUM, ANTIMONY, SILICON, ZINC AND CALCIUM, FROM WATER AND EFFLUENTS, AND THE RECOVERY, REUSE AND REGENERATION THEREOF UNIVERSIDAD DE CHILE (CL) 2025-02-20 WO disclosed
US-12162802-B2 Glasses having improved ion exchangeability and thermal expansion SCHOTT AG (DE) 2024-12-10 US disclosed
US-20240398986-A1 An oncolytic virus vector coding for interleukin-7 (IL-7) polypeptide TILT BIOTHERAPEUTICS OY (FI) 2024-12-05 US disclosed
CN-115035542-B System and method for matching a test frame sequence to a reference frame sequence 林德拉股份有限公司 2024-11-05 CN disclosed
US-20240362846-A1 SYSTEM AND METHOD FOR MATCHING A TEST FRAME SEQUENCE WITH A REFERENCE FRAME SEQUENCE LINDERA GMBH (DE) 2024-10-31 US disclosed
CN-110282874-B Glass with improved ion exchange and thermal expansion 肖特股份有限公司 2022-03-25 CN disclosed
US-11260130-B2 Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV Frequency Therapeutics, Inc. (US) 2022-03-01 US disclosed
EP-3952854-A1 COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS Frequency Therapeutics, Inc. (US) 2022-02-16 EP disclosed
US-10391070-B2 Compositions and methods for treating neurological diseases or injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-27 US disclosed
US-20180185306-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-07-05 US disclosed
US-9861596-B2 Compositions and methods for treating neurological diseases or injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-01-09 US disclosed
US-20150320702-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MEDICAL UNIVERSITY OF SOUTH CAROLINA 2015-11-12 US disclosed
WO-2014074976-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-05-15 WO disclosed
EP-2698156-A1 Phenylbutyric acid for chemoprevention Lunamed AG (CH) 2014-02-19 EP disclosed
EP-2125023-B1 SOLUBLE FORMS OF INCLUSION COMPLEXES OF HISTONE DEACETYLASE INHIBITORS AND CYCLODEXTRINS, THEIR PREPARATION PROCESSES AND USES IN THE PHARMACEUTICAL FIELD UNIV ROMA (IT) 2013-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391070-B2 Compositions and methods for treating neurological diseases or injury PROC, GLS, NLN HDAC8 2263/4885HDAC6 1759/4885HDAC7 2066/4885
US-20150320702-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY PROC, GLS, NLN HDAC8 2263/4885HDAC6 1759/4885HDAC7 2066/4885
US-20180185306-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY PROC, GLS, NLN HDAC8 2263/4885HDAC6 1759/4885HDAC7 2066/4885
US-11260130-B2 Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV GSK3B, GSK3A, GSKIP HDAC8 1102/4885HDAC6 1765/4885HDAC7 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.